title: [Effectiveness of 3-hydroxypyridine and succinic acid derivatives in complex treatment of primary open-angle glaucoma].
abstract: Prospective, placebo-controlled, single-blind, randomized clinical investigation of the influence of domestic 3-hydroxypyridine and succinic acid derivatives (emoxipin, reamberin, mexidol) on the effectiveness of a complex treatment of primary open-angle glaucoma (POAG) has been performed in a group of patients. It is established that intravenous infusion of 3-hydroxypyridine derivatives (emoxipin and mexidol) for two weeks, beginning 14 days after the start of POAG treatment, produced a retinoprotective action, with three months postponed changes in the central retinal artery (CRA) blood velocity. The retinoprotective effect of emoxipin (single dose, 150 mg) was manifested by reduction in the horizontal size of blind spot in two weeks, with the subsequent reduction of the CRA end-diastolic blood velocity observed three months after finish of the infusion therapy. The administration of mexidol (single dose, 300 mg) after 14 days of treatment led to widening of the summarized field of vision (test-object square, 16 mm), accompanied by a decrease in the electrosensitivity threshold of the optic nerve and the intensity of POAG-associated hypothymia. All indices of CRA blood velocity increased three months after termination of mexidol infusions. Reamberin (single dose, 400 ml 1,5% solution of reamberine, containing polyelectrolyte and meglumine succinate mixture) did not show retinoprotective action, but caused proatherogenic changes of blood lipids and 3 months postponed CRA end-diastolic blood velocity increase. The effect of mexidol (which is a derivative of both 3- hydroxypyridine and succinic acid) exceeds that of separate 3-hydroxypyridine (emoxipin) and succinic acid (reamberin) derivatives in the degree of retinoprotection and positive effect on the optic nerve condition and mood of POAG patients.
authors.forename: I A
authors.initials: IA
authors.lastname: Volchegorskiĭ
authors.forename: E V
authors.initials: EV
authors.lastname: Tur
authors.forename: O V
authors.initials: OV
authors.lastname: Soliannikova
authors.forename: V S
authors.initials: VS
authors.lastname: Rykun
authors.forename: M S
authors.initials: MS
authors.lastname: Sumina
authors.forename: V N
authors.initials: VN
authors.lastname: Dmitrienko
authors.forename: E V
authors.initials: EV
authors.lastname: Berdnikova
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage*; D001783:Blood Flow Velocity / Q000187:drug effects; D005260:Female; D005902:Glaucoma, Open-Angle / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008875:Middle Aged; D009898:Optic Disk / Q000503:physiopathology; D009900:Optic Nerve / Q000503:physiopathology; D010847:Picolines / Q000008:administration & dosage*; D011446:Prospective Studies; D013386:Succinates / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D000975:Antioxidants; D008055:Lipids; D010847:Picolines; C549374:Reamberin; D013386:Succinates; C070020:emoxypine succinate; D008536:Meglumine; C009820:6-methyl-2-ethyl-3-hydroxypyridine